Clinical Trials Browser

Phase 1/2 × INDUSTRY × catumaxomab × Clear all

NCT04799847 2023-02-13

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Phase 1/2 Unknown

Urinary Bladder Neoplasms